Press Releases

NorthStar Medical Technologies Receives Follow-on Award from National Nuclear Security Administration
Northstar Press Release - December 20, 2016

NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA), bringing to $11.1 million the total funded for NorthStar Medical Radioisotopes’ accelerator method of producing the medical radioisotope molybdenum-99 (Mo-99).  Read more...


James Harvey, Ph.D. of NorthStar Medical Radioisotopes to Present at NNSA 2016 Mo-99 Topical Meeting
Northstar Press Release - September 13, 2016

At the National Nuclear Security Administration’s (NNSA) 2016 Mo-99 Topical Meeting in St. Louis, NorthStar Medical Radioisotopes LLC Senior Vice President and Chief Science Officer James Harvey, Ph.D. will report on the company’s progress toward establishing a domestic supply of the medical radioisotope molybdenum-99 (Mo-99) produced without the use of highly enriched uranium (HEU).  Read more...


NorthStar Medical Radioisotopes Adds Regulatory Affairs and Engineering Leaders to its Management Team
Northstar Press Release - September 12, 2016

NorthStar Medical Radioisotopes LLC has hired James Brodack as vice president of regulatory affairs/quality assurance and Rim Milunas as vice president of engineering.  Read more...


NorthStar Medical Radioisotopes Receives Three Patents and Trademark Approval RadioGenix™ Isotope Separation System and Key Components Patented; Brand of Molybdenum-99 Trademarked
Northstar Press Release - June 10, 2016

NorthStar Medical Radioisotopes LLC has been awarded three patents and a trademark approval from the United States Patent and Trademark Office. Patents were granted for the RadioGenix™ isotope separation system and two of its key components – the Molybdenum-99 (Mo-99) Source Vessel and the Technetium-99m (Tc-99m) Product Cartridge. A trademark was awarded for NuMolium™, the company’s brand of Mo-99. Read more...


NorthStar Medical Radioisotopes Expanding MURR Operations, Quadrupling Molybdenum-99 Dispensing Capacity
Northstar Press Release - May 11, 2016

NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research Reactor (MURR) in Columbia, Missouri, adding a new filling line that will quadruple the company’s capacity there to dispense the medical radioisotope molybdenum-99 (Mo-99). Read more...


Stephen Merrick Joins NorthStar Medical Radioisotopes as COO
Northstar Press Release - May 2, 2016

Biotechnology, Pharmaceutical and Life Sciences Industry Veteran to Help Guide Company Toward FDA Approval of RadioGenix™ Isotope Separation System, Commercialization of Molybdenum-99 Production Processes. Read more...


NorthStar Medical Radioisotopes Receives $11.75 Million from National Nuclear Security Administration
Northstar Press Release - October 22, 2015

NorthStar Medical Radioisotopes LLC has received $11.75 million from the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA) for continued development and commercialization of two technologies to produce the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). Read more...


NorthStar and Westinghouse to Explore Potential New Process for Producing Medical Radioisotopes
Northstar Press Release - September 9, 2015

NorthStar Medical Radioisotopes LLC and the Westinghouse Electric Company LLC have completed a memorandum of understanding under which the companies will explore the potential for producing medical radioisotopes in commercial nuclear reactors. Of particular interest is the generation of molybdenum-99 (Mo-99) via the irradiation of molybdenum-98 (Mo-98) in the commercial nuclear reactor core. Read more...


NorthStar Medical Radioisotopes Receives Approval to Begin Routine Production of Molybdenum-99 at University of Missouri Research Reactor
Northstar Press Release - August 31, 2015

NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the University of Missouri Research Reactor (MURR) facility in Columbia, Mo. The company will now be able regularly operate its proprietary aliquoting system at the MURR site to fill source vessels with Mo-99, enabling the company to establish a weekly production schedule and increase its output of the vital medical radioisotope. Read more...


NorthStar Medical Radioisotopes Completes First Production-Scale Test Run of Molybdenum-99 Aliquoting System at the University of Missouri Research Reactor
Northstar Press Release - May 6, 2015

NorthStar Medical Radioisotopes LLC has completed its first production-scale test run of the molybdenum-99 (Mo-99) aliquoting system installed at the University of Missouri Research Reactor (MURR) in Columbia, Missouri. The test and subsequent shipment of the resulting Mo-99 to NorthStar’s Madison facility is another milestone in the establishment of domestic production of the vital medical radioisotope. Read more...


James Harvey, Ph.D. of NorthStar Medical Radioisotopes to Present at American Pharmacists Association Annual Meeting & Exposition
Northstar Press Release - March 10, 2015

James Harvey, Ph.D., senior vice president and chief science officer of NorthStar Medical Radioisotopes LLC, will be a featured speaker at the American Pharmacists Association Annual Meeting & Exposition (APhA2015) in San Diego later this month, highlighting new technologies and techniques that will create a commercially viable domestic supply of the medical radioisotope molybdenum-99 (Mo-99). Read more...


NorthStar Medical Radioisotopes Awarded Additional Funding from National Nuclear Security Administration
Northstar Press Release - November 14, 2014

NorthStar Medical Radioisotopes LLC has been awarded $5.2 million in additional funding by the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The grant supports the continued development and commercialization of the company’s neutron capture process for producing the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). Read more...


NorthStar Medical Radioisotopes Signs Letter of Intent with GE Healthcare
Northstar Press Release - August 14, 2014

NorthStar Medical Radioisotopes LLC has signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Company (NYSE: GE), marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo). Read more...


NorthStar Medical Radioisotopes Breaks Ground for New Facility in Beloit, Wis.
Northstar Press Release - July 22, 2014

NorthStar Medical Radioisotopes LLC broke ground today for a new 50,000-square-foot facility at 1800 Gateway Blvd. in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99). Read more...


NorthStar Medical Radioisotopes at the Mo-99 Topical Meeting: Chief Science Officer Reports Continued Progress Toward Non-Uranium-Based Production of Mo-99
Northstar Press Release - July 15, 2014

NorthStar Medical Radioisotopes LLC is making continued progress towards establishing a commercially viable domestic supply of the radioisotope molybdenum-99 (Mo-99). NorthStar’s chief science officer, James T. Harvey, Ph. D. provided an update on NorthStar’s progress in two presentations at the 2014 Mo-99 Topical Meeting here, June 24-27. The meeting, sponsored by National Nuclear Security Administration, brought together international and domestic policy and technical experts to report on and discuss progress toward achieving the production of Mo-99 without the use of highly enriched uranium. Read more...


NorthStar Medical Radioisotopes Signs Emissions Pledge with Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization
Northstar Press Release - June 30, 2014

NorthStar Medical Radioisotopes LLC has signed a pledge with the Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO) designed to help the CTBTO detect nuclear testing. In signing the Radioxenon Emissions Pledge, NorthStar stated that its production of the medical radioisotope molybdenum-99 (Mo-99) does not result in the emission of radioxenon, a radioactive noble gas. Based in Madison, Wis., NorthStar is one of only six producers of medical radioisotopes to have signed the pledge.  Read more...


NorthStar Medical Technologies Signs Letter of Intent with Triad Isotopes To Bring New Domestic Source of Non-HEU Materials To Market
Northstar Press Release - June 7, 2014

Signaling progress in the drive to launch the first commercially-viable domestic source of non-HEU materials, NorthStar Medical Technologies, LLC today announced the signing of a non-exclusive Letter of Intent with Triad Isotopes, Inc.  The agreement solidifies Triad’s position as an early adopter of domestically-sourced Non-HEU Molybdenum99 through NorthStar’s unique intelligent isotope separation systems, once that technology is approved by the FDA and commercially available.  Read more...


NNSA awards NorthStar Medical Technologies a Cooperative Agreement to Produce Critical Medical Isotope
Northstar Press Release - November 21, 2013

NorthStar Medical Technologies, LLC (“NorthStar”), today announced it was awarded a $21.8 million cooperative agreement of which $10.9 million will be funded by the Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The cooperative agreement is part of the NNSA’s Global Threat Reduction Initiative, which aims to accelerate the development of a reliable, domestic supply of molybdenum-99 while reducing the use of highly enriched uranium (HEU) in civilian applications worldwide.  Read more...


Wisconsin’s NorthStar Medical Technologies Secures $13.5 Million in Additional Funding for Radioisotope Production
Northstar Press Release - September 17, 2013

NorthStar Medical Technologies, LLC (“NorthStar”), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine industry, today announced the closing of a financing round totaling $13.5 million. The round was led by NorthStar’s lead investor, Hendricks Holding Company, Inc., and a group of accredited local investors. Proceeds from the financing will be used to launch commercial production of the radioisotope Molybdenum-99.  Read more...


NorthStar Medical Technologies Files New Drug Application with FDA
Northstar Press Release - March 20, 2013

NorthStar Medical Radioisotopes, LLC (NorthStar) announced that it has submitted a New Drug Application (NDA) with the Food and Drug Administration (FDA).  The FDA has accepted the application for review.  The submission is for NorthStar’s TechneGen™ Generator System, which will allow nuclear pharmacies to process radioisotopes for critical medical procedures using NorthStar’s natural, non-uranium based Molybdenum-99 (Mo99) as source material.  Read more...


NorthStar Medical Radioisotopes Awarded $22.2 Million in Federal Funds
Northstar Press Release - November 15, 2012

NorthStar Medical Radioisotopes, LLC (NorthStar), today announced that it has been awarded $22.2 million in federal funding in a Phase 2 cooperative agreement through the National Nuclear Security Administration's (NNSA) Global Threat Reduction Initiative.  Read more...


NorthStar Medical Technologies, Hendricks Commercial Properties Sign Agreement for Beloit Facility Development
Northstar Press Release - September 26, 2012

NorthStar Medical Technologies, LLC (NorthStar), today announced that it has signed an agreement with Hendricks Commercial Properties, LLC (HCP) to develop a state-of-the-art medical isotope production facility in the Gateway Business Park of Beloit, Wisconsin.  Read more...


Wisconsin's NorthStar Medical Technologies Secures $5.2 Million in Additional Funding for Safe, Domestic Radioisotope Production
Northstar Press Release - September 5, 2012

NorthStar Medical Technologies, LLC (NorthStar), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine field, today announced the closing of a Series D preferred stock financing round totaling $5.2 million. Read more...


NorthStar Medical Radioisotopes Receives Additional Funding Award for Medical Isotope Program
Northstar Press Release - November 1, 2011

NorthStar Medical Radioisotopes, LLC (NMR) has signed a follow on cooperative agreement totaling $4.6 million with the National Nuclear Security Administration's (NNSA) Global Threat Reduction Initiative for the company's medical isotope production program. Read more.


GE Hitachi Nuclear Energy and Exelon Announce the Potential Production of Critical Medical Isotope at Clinton Power Station
September 12, 2011

2011—To help address a shortage of molybdenum-99 (Mo-99), a medical isotope used in millions of medical procedures each year, GE Hitachi Nuclear Energy (GEH) and Exelon have joined to study the feasibility of producing Mo-99 at Clinton Power Station, a nuclear power plant in Clinton, Ill.. Read more...


NorthStar Medical Radioisotopes Named Winner of BioForward’s 2011 Emerging Company Showcase
September 8, 2011

NorthStar Medical Radioisotopes was among six Wisconsin bioscience companies to be selected as the winners of BioForward's 2011 Emerging Company Showcase. The showcase is part of the 2011 Bioscience Vision Summit, hosted by BioForward, the member-driven state association that is the voice of Wisconsin's bioscience industry.  Read more...


Hendricks Holdings makes Investment in NorthStar Medical Radioisotopes
NorthStar Press Release - April 7, 2011

NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has received an investment from Hendricks Holdings of Beloit, WI. The investment will allow NorthStar to rapidly pursue introduction of new technologies and production methodologies in the nuclear medicine market for molybdenum-99 and other medically significant radioisotopes. Read more...


NorthStar Medical Radioisotopes signs agreement with Missouri University to supply Molybdenum-99
NorthStar Press Release - March 1, 2011

NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has signed an agreement with the University of Missouri Research Reactor (MURR) to supply NorthStar with low specific activity molybdenum-99. Read more...